IN8bio, Inc. stock is down -6.61% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.